Payment overview · 2025
General Payments
$2,555.98
153 reported records · 22 companies
Healthcare provider profile · identity verified
Luis Melgar, MD
Allopathic & Osteopathic Physicians|Internal Medicine · DEPEW, NY · NPI 1497701965
Verified facts
What the public records show
CMS Open Payments records show Luis Melgar, MD received $2,555.98 in general payments during 2025 across 153 reported records.
AstraZeneca Pharmaceuticals LP accounted for 13.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 39 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Cuvitru, Eliquis, Mounjaro, Ozempic, Rexulti, Rybelsus, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 126 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Trulicity by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Rexulti by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XOLAIR as an associated drug or biological on 5293 records involving 2861 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Xolair by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Rybelsus by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 95 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Paxlovid by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CUVITRU as an associated drug or biological on 7118 records involving 2610 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Cuvitru by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $349.84 | 13.7% | 15 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $291.46 | 11.4% | 19 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $278.72 | 10.9% | 17 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $245.51 | 9.6% | 15 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $206.99 | 8.1% | 16 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $159.54 | 6.2% | 14 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $146.64 | 5.7% | 11 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $131.90 | 5.2% | 8 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $107.18 | 4.2% | 4 | 2025 |
| CSL Behring | Unresolved — no canonical attribution shown | $76.60 | 3.0% | 4 | 2025 |
| Grifols USA, LLC | Unresolved — no canonical attribution shown | $74.17 | 2.9% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $73.90 | 2.9% | 4 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $65.86 | 2.6% | 4 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $64.22 | 2.5% | 3 | 2025 |
| BioCryst US Sales Co., LLC | Unresolved — no canonical attribution shown | $60.89 | 2.4% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $56.85 | 2.2% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $54.37 | 2.1% | 3 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $43.46 | 1.7% | 2 | 2025 |
| ARS Pharmaceuticals Operations, Inc. | Unresolved — no canonical attribution shown | $24.73 | 1.0% | 1 | 2025 |
| Pharming Healthcare, Inc. | Unresolved — no canonical attribution shown | $18.66 | 0.7% | 1 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $15.07 | 0.6% | 1 | 2025 |
| Organon LLC | Unresolved — no canonical attribution shown | $9.42 | 0.4% | 2 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,555.98 | 153 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| DUPIXENT Normalized: dupixent |
Biological | GENZYME CORPORATION, Regeneron Healthcare Solutions, Inc. | $438.10 | 30 | 2025 |
Source payment records
|
|||||
| TEZSPIRE Normalized: tezspire |
Biological | Amgen Inc., AstraZeneca Pharmaceuticals LP | $212.43 | 10 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $173.04 | 8 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $159.08 | 10 | 2025 |
Source payment records
|
|||||
| FASENRA Normalized: fasenra |
Biological | AstraZeneca Pharmaceuticals LP | $155.33 | 6 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $131.90 | 8 | 2025 |
Source payment records
|
|||||
| CUTAQUIG Normalized: cutaquig |
Biological | PFIZER INC. | $120.95 | 7 | 2025 |
Source payment records
|
|||||
| PANZYGA Normalized: panzyga |
Biological | PFIZER INC. | $120.95 | 7 | 2025 |
Source payment records
|
|||||
| NUCALA Normalized: nucala |
Biological | GlaxoSmithKline, LLC. | $119.64 | 7 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $118.54 | 6 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $118.23 | 10 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $116.33 | 9 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $88.55 | 3 | 2025 |
Source payment records
|
|||||
| DALIRESP Normalized: daliresp |
Drug | AstraZeneca Pharmaceuticals LP | $77.31 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $66.87 | 4 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $61.22 | 3 | 2025 |
Source payment records
|
|||||
| ORLADEYO Normalized: orladeyo |
Drug | BioCryst US Sales Co., LLC | $60.89 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $58.59 | 3 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $57.32 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $56.85 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $55.69 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $43.46 | 2 | 2025 |
Source payment records
|
|||||
| Andembry Normalized: andembry |
Biological | CSL Behring | $43.17 | 2 | 2025 |
Source payment records
|
|||||
| Xembify Normalized: xembify |
Biological | Grifols USA, LLC | $41.40 | 1 | 2025 |
Source payment records
|
|||||
| CUVITRU Normalized: cuvitru |
Biological | Takeda Pharmaceuticals U.S.A., Inc. | $40.70 | 2 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $38.21 | 2 | 2025 |
Source payment records
|
|||||
| Haegarda Normalized: haegarda |
Biological | CSL Behring | $33.43 | 2 | 2025 |
Source payment records
|
|||||
| Prolastin-C Liquid Normalized: prolastin c liquid |
Biological | Grifols USA, LLC | $32.77 | 2 | 2025 |
Source payment records
|
|||||
| NEFFY Normalized: neffy |
Drug | ARS Pharmaceuticals Operations, Inc. | $24.73 | 1 | 2025 |
Source payment records
|
|||||
| HYQVIA Normalized: hyqvia |
Biological | Takeda Pharmaceuticals U.S.A., Inc. | $23.52 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $20.61 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $20.32 | 1 | 2025 |
Source payment records
|
|||||
| RUCONEST Normalized: ruconest |
Biological | Pharming Healthcare, Inc. | $18.66 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $16.16 | 1 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $15.07 | 1 | 2025 |
Source payment records
|
|||||
| VTAMA Normalized: vtama |
Drug | Organon LLC | $9.42 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $6.02 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $6.02 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $6.02 | 2 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CUVITRU cuvitru |
2025 | Cuvitru | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 95 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 66 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 126 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
126 | 23 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | XOLAIR open payments reported associated product |
CMS Open Payments — General Payments 5293 supporting records · 2861 recipient NPIs · example record 1200005083 |
Xolair · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
66 | 11 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
95 | 26 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
20 | 19 |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | CUVITRU open payments reported associated product |
CMS Open Payments — General Payments 7118 supporting records · 2610 recipient NPIs · example record 1223616510 |
Cuvitru · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 404 | 49 |
| Alprazolam | Alprazolam | 308 | 50 |
| Atorvastatin Calcium | Atorvastatin Calcium | 294 | 93 |
| Pantoprazole Sodium | Pantoprazole Sodium | 287 | 94 |
| Levothyroxine Sodium | Levothyroxine Sodium | 282 | 80 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 235 | 90 |
| Amlodipine Besylate | Amlodipine Besylate | 223 | 67 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 223 | 76 |
| Metoprolol Succinate | Metoprolol Succinate | 199 | 66 |
| Lisinopril | Lisinopril | 198 | 61 |
| Metformin Hcl | Metformin Hcl | 155 | 51 |
| Gabapentin | Gabapentin | 148 | 31 |
| Montelukast Sodium | Montelukast Sodium | 146 | 36 |
| Fluticasone Propionate | Fluticasone Propionate | 139 | 55 |
| Omeprazole | Omeprazole | 134 | 40 |
| Prednisone | Prednisone | 129 | 84 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 126 | 23 |
| Furosemide | Furosemide | 125 | 41 |
| Irbesartan | Irbesartan | 119 | 35 |
| Azithromycin | Azithromycin | 117 | 84 |
| Ibuprofen | Ibuprofen | 116 | 37 |
| Tizanidine Hcl | Tizanidine Hcl | 116 | 18 |
| Clonazepam | Clonazepam | 111 | 15 |
| Trazodone Hcl | Trazodone Hcl | 105 | 30 |
| Zolpidem Tartrate | Zolpidem Tartrate | 105 | 14 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 102 | 16 |
| Eliquis | Apixaban | 95 | 26 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 95 | 40 |
| Famotidine | Famotidine | 91 | 26 |
| Hydrochlorothiazide | Hydrochlorothiazide | 91 | 33 |
| Losartan Potassium | Losartan Potassium | 87 | 25 |
| Ezetimibe | Ezetimibe | 84 | 31 |
| Buspirone Hcl | Buspirone Hcl | 83 | 14 |
| Potassium Chloride | Potassium Chloride | 83 | 25 |
| Pregabalin | Pregabalin | 83 | 14 |
| Simvastatin | Simvastatin | 81 | 25 |
| Baclofen | Baclofen | 73 | 17 |
| Oxycodone Hcl | Oxycodone Hcl | 68 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 67 | 19 |
| Ozempic | Semaglutide | 66 | 11 |
| Bumetanide | Bumetanide | 64 | 26 |
| Duloxetine Hcl | Duloxetine Hcl | 62 | 17 |
| Tramadol Hcl | Tramadol Hcl | 62 | 15 |
| Tamsulosin Hcl | Tamsulosin Hcl | 60 | 23 |
| Celecoxib | Celecoxib | 59 | 17 |
| Sertraline Hcl | Sertraline Hcl | 57 | 19 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 55 | 17 |
| Diazepam | Diazepam | 50 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 50 | 15 |
| Pioglitazone Hcl | Pioglitazone Hcl | 50 | 15 |
| Escitalopram Oxalate | Escitalopram Oxalate | 49 | 14 |
| Allopurinol | Allopurinol | 48 | 18 |
| Meloxicam | Meloxicam | 48 | 12 |
| Clopidogrel | Clopidogrel Bisulfate | 47 | 17 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 47 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 42 | 15 |
| Clonidine Hcl | Clonidine Hcl | 41 | 13 |
| Fenofibrate | Fenofibrate,micronized | 41 | 13 |
| Warfarin Sodium | Warfarin Sodium | 40 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 39 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 38 | 24 |
| Xolair | Omalizumab | 38 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 37 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 37 | suppressed |
| Valsartan | Valsartan | 37 | suppressed |
| Atenolol | Atenolol | 36 | suppressed |
| Trulicity | Dulaglutide | 36 | suppressed |
| Jardiance | Empagliflozin | 34 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 33 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 31 | suppressed |
| Oxycontin | Oxycodone Hcl | 31 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 31 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 31 | suppressed |
| Ondansetron Odt | Ondansetron | 29 | 16 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 29 | 20 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 28 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 28 | suppressed |
| Nystatin | Nystatin | 28 | 14 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 28 | suppressed |
| Glimepiride | Glimepiride | 27 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 27 | suppressed |
| Rybelsus | Semaglutide | 27 | suppressed |
| Dupixent Pen | Dupilumab | 26 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 26 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 26 | suppressed |
| Repatha Syringe | Evolocumab | 26 | suppressed |
| Fenofibrate | Fenofibrate | 25 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 25 | suppressed |
| Lorazepam | Lorazepam | 25 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 25 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 24 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 24 | suppressed |
| Fentanyl | Fentanyl | 24 | suppressed |
| Fluconazole | Fluconazole | 24 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 24 | suppressed |
| Carvedilol | Carvedilol | 23 | suppressed |
| Methadone Hcl | Methadone Hcl | 23 | suppressed |
| Methocarbamol | Methocarbamol | 23 | suppressed |
| Mirtazapine | Mirtazapine | 23 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 23 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 22 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 22 | suppressed |
| Glipizide Er | Glipizide | 21 | suppressed |
| Vascepa | Icosapent Ethyl | 21 | suppressed |
| Lovastatin | Lovastatin | 20 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 20 | 19 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 19 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 19 | suppressed |
| Synthroid | Levothyroxine Sodium | 19 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 18 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 18 | suppressed |
| Bupropion Xl | Bupropion Hcl | 18 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 18 | suppressed |
| Gemfibrozil | Gemfibrozil | 18 | suppressed |
| Levofloxacin | Levofloxacin | 18 | 14 |
| Pentoxifylline | Pentoxifylline | 18 | suppressed |
| Topiramate | Topiramate | 18 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 17 | suppressed |
| Metolazone | Metolazone | 17 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 16 | 14 |
| Glipizide | Glipizide | 16 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 16 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 16 | suppressed |
| Sucralfate | Sucralfate | 16 | suppressed |
| Amoxicillin | Amoxicillin | 15 | suppressed |
| Cefdinir | Cefdinir | 15 | 13 |
| Fenofibrate | Fenofibrate Nanocrystallized | 15 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 15 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 15 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 15 | suppressed |
| Movantik | Naloxegol Oxalate | 15 | suppressed |
| Spironolactone | Spironolactone | 15 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 15 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 14 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 14 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 14 | 12 |
| Icosapent Ethyl | Icosapent Ethyl | 14 | suppressed |
| Loperamide | Loperamide Hcl | 14 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 14 | suppressed |
| Mounjaro | Tirzepatide | 14 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 14 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 14 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 14 | suppressed |
| Epinephrine | Epinephrine | 13 | 13 |
| Ketoconazole | Ketoconazole | 13 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 13 | suppressed |
| Pilocarpine Hcl | Pilocarpine Hcl | 13 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 12 | suppressed |
| Buprenorphine | Buprenorphine | 12 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Tradjenta | Linagliptin | 12 | suppressed |
| Cuvitru | Immun Glob G(Igg)/Gly/Iga Ov50 | 11 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 11 | suppressed |
| Metronidazole | Metronidazole | 11 | suppressed |
| Repatha Sureclick | Evolocumab | 11 | suppressed |
| Rexulti | Brexpiprazole | 11 | suppressed |
| Sf 5000 Plus | Fluoride (Sodium) | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,555.98 · 153 records | AstraZeneca Pharmaceuticals LP | ABRYSVO, AIRSUPRA, AREXVY, Andembry, Auvelity, COMIRNATY, CUTAQUIG, CUVITRU, Cologuard Collection Kit, DALIRESP, DUPIXENT, ELIQUIS, FARXIGA, FASENRA, HYQVIA, Haegarda, Leqembi, MOUNJARO, NEFFY, NUCALA, NURTEC ODT, ORLADEYO, OTEZLA, Ozempic, PANZYGA, PREVNAR 20, Prolastin-C Liquid, REPATHA, REXULTI, RUCONEST, Rybelsus, TEZSPIRE, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, VOQUEZNA, VTAMA, Xembify, ZAVZPRET, ZEPBOUND | 13 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Cuvitru play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error